• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤免疫微环境受胃癌的移码突变和肿瘤突变负担影响。

Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer.

机构信息

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

出版信息

Clin Transl Oncol. 2022 Mar;24(3):556-567. doi: 10.1007/s12094-021-02714-6. Epub 2021 Nov 12.

DOI:10.1007/s12094-021-02714-6
PMID:34767183
Abstract

PURPOSE

Immunoscore can effectively predict prognosis in patients with colon cancer; however, its clinical application is limited. We modified the Immunoscore and created a tumor immune microenvironment (TIM) classification system for gastric carcinoma. Unlike previous studies that used small sample sizes or focused on particular immune-cell subtypes, our simplified system enables pathologists to classify gastric carcinomas intuitively using H&E-stained sections.

METHODS

Samples from 326 patients with advanced gastric carcinoma were reviewed and analyzed by pathologists using simple determination and digital image analysis. Comprehensive results of cancer-panel sequencing, Epstein-Barr‒virus (EBV) status, and PD-L1, HER2, ATM, PTEN, MET, FGFR2, and EGFR immunohistochemistry were evaluated with respect to the TIM class.

RESULTS

The TIM was classified as "hot" (n = 22), "immunosuppressed" (n = 178), "excluded" (n = 83), or "cold" (n = 43). TIM category was significantly associated with numbers of frameshift mutations (P < 0.001) and high tumor mutational burden (P < 0.004), and predicted overall survival. It was also significantly associated with age, histological type, degree of fibrosis, PD-L1 expression, loss of ATM and PTEN expression (P < 0.001), sex, EBV positivity, and HER2 overexpression (P < 0.04). "Hot" tumors were frequent in PD-L1 expressing and EBV-positive samples, and in those with ATM and PTEN loss. "Excluded" tumors were frequent in HER2-positive cases, whereas "cold" tumors were more frequent in younger patients with poorly cohesive histology and high fibrosis levels.

CONCLUSIONS

TIM classification system for gastric carcinoma has prognostic significance and results in classes that are associated with molecular characteristics.

摘要

目的

免疫评分可有效预测结肠癌患者的预后,但临床应用受限。我们对免疫评分进行了改良,并创建了一个用于胃癌的肿瘤免疫微环境(TIM)分类系统。与以往使用小样本量或专注于特定免疫细胞亚型的研究不同,我们的简化系统使病理学家能够使用 H&E 染色切片直观地对胃癌进行分类。

方法

对 326 例晚期胃癌患者的样本进行回顾性分析,由病理学家使用简单判定和数字图像分析进行分析。综合评估了癌症panel 测序、EBV 状态以及 PD-L1、HER2、ATM、PTEN、MET、FGFR2 和 EGFR 的免疫组化结果,根据 TIM 分类进行评估。

结果

TIM 分为“热”(n=22)、“免疫抑制”(n=178)、“排除”(n=83)或“冷”(n=43)。TIM 类别与移码突变数量(P<0.001)和高肿瘤突变负担(P<0.004)显著相关,与总生存期相关。它还与年龄、组织学类型、纤维化程度、PD-L1 表达、ATM 和 PTEN 表达缺失(P<0.001)、性别、EBV 阳性和 HER2 过表达(P<0.04)显著相关。“热”肿瘤在 PD-L1 表达阳性和 EBV 阳性样本中以及在 ATM 和 PTEN 缺失的样本中更为常见。“排除”肿瘤在 HER2 阳性病例中更为常见,而“冷”肿瘤在年轻、具有高纤维化为特征、组织学黏附性差的患者中更为常见。

结论

胃癌 TIM 分类系统具有预后意义,并与分子特征相关联。

相似文献

1
Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer.肿瘤免疫微环境受胃癌的移码突变和肿瘤突变负担影响。
Clin Transl Oncol. 2022 Mar;24(3):556-567. doi: 10.1007/s12094-021-02714-6. Epub 2021 Nov 12.
2
Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type.根据肿瘤微环境免疫类型分析 II 期和 III 期胃癌的体细胞突变特征。
Genes Chromosomes Cancer. 2019 Jan;58(1):12-22. doi: 10.1002/gcc.22683. Epub 2018 Oct 16.
3
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.胃腺癌中 PD-L1 联合肿瘤浸润淋巴细胞、EB 病毒和微卫星不稳定性的预后预测。
Diagn Pathol. 2020 Jun 4;15(1):69. doi: 10.1186/s13000-020-00979-z.
4
New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.深入了解富含淋巴细胞基质的胃癌炎症肿瘤免疫微环境:从形态学和数字分析到基因表达。
Gastric Cancer. 2019 Jan;22(1):77-90. doi: 10.1007/s10120-018-0836-8. Epub 2018 May 19.
5
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.II期和III期胃癌患者中基于PD-L1表达和CD8阳性肿瘤浸润淋巴细胞的免疫分类的临床病理意义
Oncotarget. 2017 Apr 18;8(16):26356-26367. doi: 10.18632/oncotarget.15465.
6
The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.PD-1、PD-L1表达及CD3+ T细胞浸润与晚期胃印戒细胞癌预后的关系,是免疫治疗的潜在生物标志物。
Oncotarget. 2017 Jun 13;8(24):38850-38862. doi: 10.18632/oncotarget.16407.
7
Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.不同分子亚型胃癌之间免疫结构的差异及其对预后的影响。
Gastric Cancer. 2019 Nov;22(6):1164-1175. doi: 10.1007/s10120-019-00974-4. Epub 2019 May 31.
8
Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.根据 EBV 感染强度的不同,胃癌微环境存在差异:这对可能的免疫辅助治疗具有启示意义。
PLoS Pathog. 2013;9(5):e1003341. doi: 10.1371/journal.ppat.1003341. Epub 2013 May 9.
9
Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.胃淋巴基质癌:组织病理学和分子特征评估。
Am J Surg Pathol. 2018 Apr;42(4):453-462. doi: 10.1097/PAS.0000000000001018.
10
Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.免疫抑制蛋白表达以及肿瘤微环境中免疫细胞浸润在胃癌中的预后意义。
Gastric Cancer. 2016 Jan;19(1):42-52. doi: 10.1007/s10120-014-0440-5. Epub 2014 Nov 26.

引用本文的文献

1
Retrospective study on the prognostic prediction of inflammatory markers and the C-reactive protein/albumin ratio in first-line immunotherapy for advanced HER2 negative gastric cancer patients.晚期HER2阴性胃癌患者一线免疫治疗中炎症标志物及C反应蛋白/白蛋白比值预后预测的回顾性研究
Transl Cancer Res. 2025 Mar 30;14(3):2043-2053. doi: 10.21037/tcr-2025-192. Epub 2025 Mar 17.
2
Poorly cohesive gastric cancer with increased epithelial‑mesenchymal transition is associated with a poor prognosis.具有上皮-间质转化增加的低黏附性胃癌与预后不良相关。
Oncol Lett. 2024 Jul 3;28(3):420. doi: 10.3892/ol.2024.14554. eCollection 2024 Sep.
3

本文引用的文献

1
Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients.免疫评分可预测早期肺腺癌患者的生存率。
Front Oncol. 2020 May 8;10:691. doi: 10.3389/fonc.2020.00691. eCollection 2020.
2
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga.结直肠癌的免疫基因组学:关于一个不断发展的故事的事实与假说
Trends Cancer. 2019 Dec;5(12):779-788. doi: 10.1016/j.trecan.2019.10.006. Epub 2019 Nov 6.
3
Use of immunotherapy in the treatment of gastric cancer.免疫疗法在胃癌治疗中的应用。
Exploring the molecular mechanisms network of breast cancer by multi-omics analysis.
通过多组学分析探索乳腺癌的分子机制网络。
Asia Pac J Clin Oncol. 2025 Feb;21(1):129-137. doi: 10.1111/ajco.14052. Epub 2024 Mar 13.
4
Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.评价 ITGB1 表达作为预测胃癌免疫检查点抑制剂治疗效果的指标。
BMC Gastroenterol. 2023 Sep 4;23(1):298. doi: 10.1186/s12876-023-02930-0.
5
Upregulation of Apolipoprotein L6 Improves Tumor Immunotherapy by Inducing Immunogenic Cell Death.载脂蛋白 L6 的上调通过诱导免疫原性细胞死亡来改善肿瘤免疫治疗。
Biomolecules. 2023 Feb 22;13(3):415. doi: 10.3390/biom13030415.
6
Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion.EBV 相关胃腺癌中的浸润 T 细胞表现出高水平的多种激活标志物、效应基因表达和耗竭。
Viruses. 2023 Jan 7;15(1):176. doi: 10.3390/v15010176.
7
A Novel Prognostic Chemokine-Related lncRNAs Signature Associated with Immune Landscape in Colon Adenocarcinoma.一种与结肠癌免疫图谱相关的新型预后趋化因子相关 lncRNAs 标志物。
Dis Markers. 2022 Nov 3;2022:2823042. doi: 10.1155/2022/2823042. eCollection 2022.
8
BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression.仅具有高肿瘤突变负担的 BAT26 微卫星不稳定性-一种与 PTEN 蛋白缺失和高 PD-L1 表达相关的罕见实体。
Int J Mol Sci. 2022 Sep 14;23(18):10730. doi: 10.3390/ijms231810730.
9
Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.胃腺癌中异常 SWI/SNF 复合物亚基 PBRM1 的临床病理意义、相关分子变化及肿瘤免疫反应分析。
Pathol Oncol Res. 2022 Jul 19;28:1610479. doi: 10.3389/pore.2022.1610479. eCollection 2022.
10
Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.胃癌:机制、生物标志物与治疗方法
Biomedicines. 2022 Feb 24;10(3):543. doi: 10.3390/biomedicines10030543.
Oncol Lett. 2019 Dec;18(6):5681-5690. doi: 10.3892/ol.2019.10935. Epub 2019 Sep 30.
4
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?癌症免疫治疗中的外周免疫相关生物标志物:我们能否实现其预测潜能?
J Immunother Cancer. 2019 Nov 27;7(1):325. doi: 10.1186/s40425-019-0799-2.
5
The 2019 WHO classification of tumours of the digestive system.2019年世界卫生组织消化系统肿瘤分类。
Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975. Epub 2019 Nov 13.
6
The Immunoscore: Colon Cancer and Beyond.免疫评分:结肠癌及其他癌症
Clin Cancer Res. 2020 Jan 15;26(2):332-339. doi: 10.1158/1078-0432.CCR-18-1851. Epub 2019 Aug 14.
7
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.迈向全面认识癌症免疫反应性:SITC 研讨会综述。
J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4.
8
Bridging genomics and phenomics of gastric carcinoma.胃癌的基因组学与表型组学研究进展
Int J Cancer. 2019 Nov 1;145(9):2407-2417. doi: 10.1002/ijc.32228. Epub 2019 Mar 18.
9
Immunotherapy in advanced gastric cancer, is it the future?免疫治疗在晚期胃癌中的应用,是否代表未来?
Crit Rev Oncol Hematol. 2019 Jan;133:25-32. doi: 10.1016/j.critrevonc.2018.10.007. Epub 2018 Nov 2.
10
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.采用联合免疫疗法治疗免疫热、改变和冷肿瘤的方法。
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. doi: 10.1038/s41573-018-0007-y.